Cargando…
Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab
INTRODUCTION: In immunocompromised patients, Epstein-Barr virus (EBV) infection or reactivation is associated with increased morbidity and mortality, including the development of B-cell lymphomas. The first-line treatment consists of reduction of immunosuppression and administration of rituximab (an...
Autores principales: | Tischer-Zimmermann, Sabine, Bonifacius, Agnes, Santamorena, Maria Michela, Mausberg, Philip, Stoll, Sven, Döring, Marius, Kalinke, Ulrich, Blasczyk, Rainer, Maecker-Kolhoff, Britta, Eiz-Vesper, Britta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079996/ https://www.ncbi.nlm.nih.gov/pubmed/37033971 http://dx.doi.org/10.3389/fimmu.2023.878953 |
Ejemplares similares
-
Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes
por: Bieling, Maren, et al.
Publicado: (2017) -
Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
por: Mika, Thomas, et al.
Publicado: (2019) -
Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry
por: Eiz-Vesper, Britta, et al.
Publicado: (2013) -
Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease
por: Schultze-Florey, Rebecca E., et al.
Publicado: (2018) -
CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
por: Dragon, Anna Christina, et al.
Publicado: (2020)